Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Multiple Sclerosis Treatment Devices Market

ID: MRFR/HC/57635-CR
161 Pages
Rahul Gotadki
Last Updated: April 24, 2026

Multiple Sclerosis Treatment Devices Market Research Report Information by Type (Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Relapsing-remitting Multiple Sclerosis (RRMS), Clinically Isolated Syndrome (CIS)), by Treatment Devices (Electrical Stimulation Devices (Functional Electrical Stimulation (FES), Transcutaneous Electrical Nerve Stimulation (TENS)), Neurostimulation Devices (Spinal Cord Stimulation (SCS), Deep Brain Stimulation (DBS))), by End-User (Hospitals & Clinics, Ambulatory Surgical Centers) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa) - Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Multiple Sclerosis Treatment Devices Market  Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Type (USD Billion) | |
      1. 4.1.1 Primary Progressive Multiple Sclerosis (PPMS) | |
      2. 4.1.2 Secondary Progressive Multiple Sclerosis (SPMS) | |
      3. 4.1.3 Relapsing-remitting Multiple Sclerosis (RRMS) | |
      4. 4.1.4 Clinically Isolated Syndrome (CIS) |
    2. 4.2 Healthcare, BY Treatment Devices (USD Billion) | |
      1. 4.2.1 Electrical Stimulation Devices | |
      2. 4.2.2 Neurostimulation Devices |
    3. 4.3 Healthcare, BY End-User (USD Billion) | |
      1. 4.3.1 Hospitals & Clinics | |
      2. 4.3.2 Ambulatory Surgical Centers |
    4. 4.4 Healthcare, BY Region (USD Billion) | |
      1. 4.4.1 North America | | |
        1. 4.4.1.1 US | | |
        2. 4.4.1.2 Canada | |
      2. 4.4.2 Europe | | |
        1. 4.4.2.1 Germany | | |
        2. 4.4.2.2 UK | | |
        3. 4.4.2.3 France | | |
        4. 4.4.2.4 Russia | | |
        5. 4.4.2.5 Italy | | |
        6. 4.4.2.6 Spain | | |
        7. 4.4.2.7 Rest of Europe | |
      3. 4.4.3 APAC | | |
        1. 4.4.3.1 China | | |
        2. 4.4.3.2 India | | |
        3. 4.4.3.3 Japan | | |
        4. 4.4.3.4 South Korea | | |
        5. 4.4.3.5 Malaysia | | |
        6. 4.4.3.6 Thailand | | |
        7. 4.4.3.7 Indonesia | | |
        8. 4.4.3.8 Rest of APAC | |
      4. 4.4.4 South America | | |
        1. 4.4.4.1 Brazil | | |
        2. 4.4.4.2 Mexico | | |
        3. 4.4.4.3 Argentina | | |
        4. 4.4.4.4 Rest of South America | |
      5. 4.4.5 MEA | | |
        1. 4.4.5.1 GCC Countries | | |
        2. 4.4.5.2 South Africa | | |
        3. 4.4.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Novartis (CH) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Biogen (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Sanofi (FR) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Merck KGaA (DE) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Genzyme (US) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 AbbVie (US) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Eisai Co., Ltd. (JP) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY TYPE |
    7. 6.4 US MARKET ANALYSIS BY TREATMENT DEVICES |
    8. 6.5 US MARKET ANALYSIS BY END-USER |
    9. 6.6 CANADA MARKET ANALYSIS BY TYPE |
    10. 6.7 CANADA MARKET ANALYSIS BY TREATMENT DEVICES |
    11. 6.8 CANADA MARKET ANALYSIS BY END-USER |
    12. 6.9 EUROPE MARKET ANALYSIS |
    13. 6.10 GERMANY MARKET ANALYSIS BY TYPE |
    14. 6.11 GERMANY MARKET ANALYSIS BY TREATMENT DEVICES |
    15. 6.12 GERMANY MARKET ANALYSIS BY END-USER |
    16. 6.13 UK MARKET ANALYSIS BY TYPE |
    17. 6.14 UK MARKET ANALYSIS BY TREATMENT DEVICES |
    18. 6.15 UK MARKET ANALYSIS BY END-USER |
    19. 6.16 FRANCE MARKET ANALYSIS BY TYPE |
    20. 6.17 FRANCE MARKET ANALYSIS BY TREATMENT DEVICES |
    21. 6.18 FRANCE MARKET ANALYSIS BY END-USER |
    22. 6.19 RUSSIA MARKET ANALYSIS BY TYPE |
    23. 6.20 RUSSIA MARKET ANALYSIS BY TREATMENT DEVICES |
    24. 6.21 RUSSIA MARKET ANALYSIS BY END-USER |
    25. 6.22 ITALY MARKET ANALYSIS BY TYPE |
    26. 6.23 ITALY MARKET ANALYSIS BY TREATMENT DEVICES |
    27. 6.24 ITALY MARKET ANALYSIS BY END-USER |
    28. 6.25 SPAIN MARKET ANALYSIS BY TYPE |
    29. 6.26 SPAIN MARKET ANALYSIS BY TREATMENT DEVICES |
    30. 6.27 SPAIN MARKET ANALYSIS BY END-USER |
    31. 6.28 REST OF EUROPE MARKET ANALYSIS BY TYPE |
    32. 6.29 REST OF EUROPE MARKET ANALYSIS BY TREATMENT DEVICES |
    33. 6.30 REST OF EUROPE MARKET ANALYSIS BY END-USER |
    34. 6.31 APAC MARKET ANALYSIS |
    35. 6.32 CHINA MARKET ANALYSIS BY TYPE |
    36. 6.33 CHINA MARKET ANALYSIS BY TREATMENT DEVICES |
    37. 6.34 CHINA MARKET ANALYSIS BY END-USER |
    38. 6.35 INDIA MARKET ANALYSIS BY TYPE |
    39. 6.36 INDIA MARKET ANALYSIS BY TREATMENT DEVICES |
    40. 6.37 INDIA MARKET ANALYSIS BY END-USER |
    41. 6.38 JAPAN MARKET ANALYSIS BY TYPE |
    42. 6.39 JAPAN MARKET ANALYSIS BY TREATMENT DEVICES |
    43. 6.40 JAPAN MARKET ANALYSIS BY END-USER |
    44. 6.41 SOUTH KOREA MARKET ANALYSIS BY TYPE |
    45. 6.42 SOUTH KOREA MARKET ANALYSIS BY TREATMENT DEVICES |
    46. 6.43 SOUTH KOREA MARKET ANALYSIS BY END-USER |
    47. 6.44 MALAYSIA MARKET ANALYSIS BY TYPE |
    48. 6.45 MALAYSIA MARKET ANALYSIS BY TREATMENT DEVICES |
    49. 6.46 MALAYSIA MARKET ANALYSIS BY END-USER |
    50. 6.47 THAILAND MARKET ANALYSIS BY TYPE |
    51. 6.48 THAILAND MARKET ANALYSIS BY TREATMENT DEVICES |
    52. 6.49 THAILAND MARKET ANALYSIS BY END-USER |
    53. 6.50 INDONESIA MARKET ANALYSIS BY TYPE |
    54. 6.51 INDONESIA MARKET ANALYSIS BY TREATMENT DEVICES |
    55. 6.52 INDONESIA MARKET ANALYSIS BY END-USER |
    56. 6.53 REST OF APAC MARKET ANALYSIS BY TYPE |
    57. 6.54 REST OF APAC MARKET ANALYSIS BY TREATMENT DEVICES |
    58. 6.55 REST OF APAC MARKET ANALYSIS BY END-USER |
    59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
    60. 6.57 BRAZIL MARKET ANALYSIS BY TYPE |
    61. 6.58 BRAZIL MARKET ANALYSIS BY TREATMENT DEVICES |
    62. 6.59 BRAZIL MARKET ANALYSIS BY END-USER |
    63. 6.60 MEXICO MARKET ANALYSIS BY TYPE |
    64. 6.61 MEXICO MARKET ANALYSIS BY TREATMENT DEVICES |
    65. 6.62 MEXICO MARKET ANALYSIS BY END-USER |
    66. 6.63 ARGENTINA MARKET ANALYSIS BY TYPE |
    67. 6.64 ARGENTINA MARKET ANALYSIS BY TREATMENT DEVICES |
    68. 6.65 ARGENTINA MARKET ANALYSIS BY END-USER |
    69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE |
    70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT DEVICES |
    71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY END-USER |
    72. 6.69 MEA MARKET ANALYSIS |
    73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY TYPE |
    74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT DEVICES |
    75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY END-USER |
    76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY TYPE |
    77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT DEVICES |
    78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY END-USER |
    79. 6.76 REST OF MEA MARKET ANALYSIS BY TYPE |
    80. 6.77 REST OF MEA MARKET ANALYSIS BY TREATMENT DEVICES |
    81. 6.78 REST OF MEA MARKET ANALYSIS BY END-USER |
    82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
    83. 6.80 RESEARCH PROCESS OF MRFR |
    84. 6.81 DRO ANALYSIS OF HEALTHCARE |
    85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
    88. 6.85 HEALTHCARE, BY TYPE, 2024 (% SHARE) |
    89. 6.86 HEALTHCARE, BY TYPE, 2024 TO 2035 (USD Billion) |
    90. 6.87 HEALTHCARE, BY TREATMENT DEVICES, 2024 (% SHARE) |
    91. 6.88 HEALTHCARE, BY TREATMENT DEVICES, 2024 TO 2035 (USD Billion) |
    92. 6.89 HEALTHCARE, BY END-USER, 2024 (% SHARE) |
    93. 6.90 HEALTHCARE, BY END-USER, 2024 TO 2035 (USD Billion) |
    94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    95. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY END-USER, 2025-2035 (USD Billion) |
    97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY END-USER, 2025-2035 (USD Billion) |
    98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY END-USER, 2025-2035 (USD Billion) |
    99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY END-USER, 2025-2035 (USD Billion) |
    100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY END-USER, 2025-2035 (USD Billion) |
    101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY END-USER, 2025-2035 (USD Billion) |
    102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY END-USER, 2025-2035 (USD Billion) |
    103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY END-USER, 2025-2035 (USD Billion) |
    104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY END-USER, 2025-2035 (USD Billion) |
    105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY END-USER, 2025-2035 (USD Billion) |
    106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY END-USER, 2025-2035 (USD Billion) |
    107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY END-USER, 2025-2035 (USD Billion) |
    108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY END-USER, 2025-2035 (USD Billion) |
    109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY END-USER, 2025-2035 (USD Billion) |
    110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY END-USER, 2025-2035 (USD Billion) |
    111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY END-USER, 2025-2035 (USD Billion) |
    112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY END-USER, 2025-2035 (USD Billion) |
    113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY END-USER, 2025-2035 (USD Billion) |
    114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY END-USER, 2025-2035 (USD Billion) |
    115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY END-USER, 2025-2035 (USD Billion) |
    116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY END-USER, 2025-2035 (USD Billion) |
    117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY END-USER, 2025-2035 (USD Billion) |
    118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY END-USER, 2025-2035 (USD Billion) |
    119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY END-USER, 2025-2035 (USD Billion) |
    120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY END-USER, 2025-2035 (USD Billion) |
    121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY END-USER, 2025-2035 (USD Billion) |
    122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY END-USER, 2025-2035 (USD Billion) |
    123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY END-USER, 2025-2035 (USD Billion) |
    124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY TYPE, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY TREATMENT DEVICES, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY END-USER, 2025-2035 (USD Billion) |
    125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    126. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Type (USD Billion, 2025-2035)

  • Primary Progressive Multiple Sclerosis (PPMS)
  • Secondary Progressive Multiple Sclerosis (SPMS)
  • Relapsing-remitting Multiple Sclerosis (RRMS)
  • Clinically Isolated Syndrome (CIS)

Healthcare By Treatment Devices (USD Billion, 2025-2035)

  • Electrical Stimulation Devices
  • Neurostimulation Devices

Healthcare By End-User (USD Billion, 2025-2035)

  • Hospitals & Clinics
  • Ambulatory Surgical Centers

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions